Ez-PAVE Study Proves Superiority of Intensive Therapy: Potential Shift in Heart Guidelines
The longstanding clinical debate over “how low is low enough” for cholesterol management has reached a pivotal turning point. Latest data from the Ez-PAVE trial suggests that pushing LDL-C targets below 55 mg/dL provides a statistically significant shield against major cardiovascular events for high-risk patients.
Key Clinical Takeaways:
- Aggressive LDL-C targeting (<55 mg/dL) reduced the risk of major adverse cardiovascular events (MACE) by 33% compared to conventional targets (<70 mg/dL).
- The benefit was primarily driven by a reduction in nonfatal myocardial infarction (MI) and the require for revascularization.
- The study confirms the “lower is better” hypothesis in a real-world clinical setting without the exclusive reliance on high-cost PCSK9 inhibitors.
The Clinical Gap in ASCVD Secondary Prevention
For years, a tension existed between international guidelines and bedside practice. While European guidelines had already suggested an LDL-C target of less than 55 mg/dL for patients with atherosclerotic cardiovascular disease (ASCVD), the lack of head-to-head, randomized controlled trial (RCT) evidence left many clinicians hesitant. In practice, the 70 mg/dL threshold remained the default standard of care, leaving a critical question unanswered: does further reduction actually translate to fewer deaths and heart attacks, or is it merely a numerical exercise?
The pathogenesis of ASCVD involves the gradual accumulation of cholesterol-rich plaques within arterial walls. When these plaques rupture, they trigger thrombotic events—such as myocardial infarction or stroke—that lead to significant morbidity. The Ez-PAVE trial was designed specifically to bridge this evidence gap, testing whether a more aggressive lipid-lowering strategy could fundamentally alter the trajectory of the disease for those already diagnosed with high-risk conditions.
Ez-PAVE: A Rigorous Clinical Breakdown
Conducted between January 2021 and July 2022 across 17 medical institutions in South Korea, the Ez-PAVE study enrolled 3,048 patients. The cohort was defined by a history of ASCVD, encompassing patients with previous acute coronary syndrome, stable angina (verified by imaging or functional studies), coronary or arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease.
Patients were randomized into two distinct cohorts: an intensive-target group aiming for LDL-C <55 mg/dL and a conventional-target group aiming for <70 mg/dL. Treatment was left to the clinician’s discretion, mirroring real-world practice by utilizing high-intensity statins, ezetimibe, and PCSK9 inhibitors as required. The primary endpoint was a composite of cardiovascular death, nonfatal MI, nonfatal stroke, any revascularization, or hospitalization for unstable angina.
| Clinical Metric | Intensive Group (<55 mg/dL) | Conventional Group (<70 mg/dL) |
|---|---|---|
| Patient Enrollment (n) | 1,526 | 1,522 |
| Median LDL-C Achieved | 56 mg/dL | 66 mg/dL |
| MACE Incidence (3 Years) | 6.6% (n=100) | 9.7% (n=147) |
| Relative Risk Reduction | 33% | Reference |
| Mean Patient Age | 64 years | 64 years |
The trial’s integrity was further bolstered by a secondary analysis. Because the study used an open-label design, researchers feared that the subjective nature of revascularization decisions might bias the results. To counter this, they performed an analysis excluding revascularization from the primary endpoint; the superiority of the intensive group remained intact, validating the objective clinical benefit of the lower target.
“Guidelines were mentioning 55 mg/dL, but in actual clinical practice, no one was seriously treating that number as a target,” stated Professor Lee Yong-jun of Sinchon Severance Hospital, highlighting the disconnect that prompted the Ez-PAVE research.
Translating Data into Patient Care
The reduction in MACE was not uniform across all event types; it was most pronounced in the prevention of nonfatal myocardial infarctions and the requirement for revascularization procedures. This suggests that maintaining an LDL-C level below 55 mg/dL may stabilize existing plaques more effectively, preventing the acute ruptures that lead to emergency interventions. This “lower is better” efficacy was achieved through a combination of therapies, including the use of rosuvastatin and ezetimibe, proving that aggressive targets are attainable without relying solely on expensive biologics.
For patients currently managed under the older 70 mg/dL standard, this shift in evidence necessitates a review of their current pharmacological regimen. Transitioning to an intensive target often requires a nuanced titration of medication to avoid contraindications or adverse effects. It is highly recommended that patients consult with lipid management specialists to determine if they are candidates for this more aggressive approach.
the complexity of managing ASCVD—especially in patients with comorbid stroke or peripheral artery disease—requires a multidisciplinary approach. Coordinating care through board-certified cardiologists ensures that lipid-lowering goals are integrated with overall hemodynamic stability and blood pressure management.
Transparency and Institutional Support
The findings of the Ez-PAVE trial were presented during a Late-Breaking Clinical Trials session at the American College of Cardiology (ACC.26) in New Orleans and published in the New England Journal of Medicine (NEJM). The research and subsequent dissemination of results were supported by Yuhan Corporation, emphasizing the role of pharmaceutical partnership in generating high-evidence clinical data for the medical community.
The study contributes to a growing body of global research hosted on platforms like PubMed and the American College of Cardiology, which continue to refine the standard of care for dyslipidemia. By providing the first randomized, head-to-head comparison of these two specific targets, Ez-PAVE offers the empirical weight necessary to potentially shift global guidelines toward a more aggressive stance on LDL-C reduction.
The trajectory of cardiovascular medicine is moving toward precision prevention. As the evidence for the 55 mg/dL target solidifies, the focus will shift from whether we should lower cholesterol further, to how You can do so safely and equitably across diverse patient populations. For those seeking to optimize their cardiovascular health or requiring advanced screening for ASCVD, accessing advanced diagnostic centers is the first step in establishing a personalized, evidence-based treatment plan.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.